NCT03867617 Cell Therapy for Immunomodulation in Kidney Transplantation Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03866239 A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma Status TERMINATED Phase PHASE1
NCT03821246 Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Status RECRUITING Phase PHASE2
NCT03787290 Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder Status SUSPENDED Phase PHASE2
NCT03781310 Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Status UNKNOWN Phase PHASE4
NCT03745586 Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Status COMPLETED Phase PHASE1/PHASE2
NCT03737708 A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) Status COMPLETED Phase PHASE4
NCT03708224 Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Status RECRUITING Phase PHASE2
NCT03699631 PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant Status COMPLETED Phase PHASE2
NCT03677154 Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT03677141 A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT03671018 A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03588936 Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Status TERMINATED Phase PHASE1
NCT03564340 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Status RECRUITING Phase PHASE1/PHASE2
NCT03539484 A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors Status TERMINATED Phase PHASE1
NCT03533283 An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03533101 Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Status COMPLETED Phase PHASE1/PHASE2
NCT03522012 Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers Status COMPLETED Phase PHASE1